The aim of this study is to evaluate the efficacy of Conbercept in the treatment of wet age-related macular degeneration (AMD) using the optical coherence tomography angiography (OCTA).

32 patients (40 eyes) diagnosed with wet AMD from the Department of Ophthalmology, Affiliated Hospital of Inner Mongolia University for Nationalities from April 2016 to December 2018 were collected retrospectively. Among of them, there were 19 males (23 eyes) and 13 females (17 eyes); they were 54 to 83 years-old with an average age of (68.0±7.5) years-old. After 3 consecutive monthly injections, they were switched to an on-demand treatment plan for treatment. The patient′s preoperative, 1 day, 3 days, 7 days, 1 month, 2 months, 3 months and 6 months after the operation best corrected visual acuity (BCVA), fluorescein fundus angiography (FFA) leakage, retinal structure integrity, central macular thickness (CMT) and choroidal neovascularization ( CNV) area were recorded. At different time points before and after treatment, BCVA, CNV area, and CMT were tested for normality and conformed to normal distribution. The mean±standard deviation was used for description. The comparison before and after treatment was used single-factor repeated measures analysis of variance. When the difference is statistically significant, further pairwise was comparised.

Among of 32 cases (40 eyes) of wet AMD, there were 10 cases (12 eyes) with type 1 CNV, accounting for 31.2%; 22 cases (28 eyes) with type 2 CNV, accounting for 68.8%. After treatment for 6 months, macular edema, exudation, fluorescein leakage, retinal pigment epithelium protrusion and neocapillaries subsided in wet AMD patients with type 1 CNV and type 2 CNV. The preoperative BCVA, CNV area and CMT of eyes with wet AMD were (0.78±0.46), (1.56±0.92) mm², (304.73±121.27) μm, respectively; after treat-ment for 6 months, the BCVA, CNV area and CMT of eyes with wet AMD were (0.51±0.35), (1.18±0.79) mm², (235.90±62.18) μm, respectively. There were significant differences in BCVA, CNV area and CMT before and after treatment at different time points (F= 6.878, 6.952, 5.365; P<0.05). For further comparison, after t testing, the differences in BCVA, CNV area and CMT of patients before and after treatment for 6 months were statistically significant (t=4.19, 3.96, 3.58; P<0.05).

OCTA could visually and clearly display the morphology of CNV lesions, and quantify indices such as CMT, CNV area, etc., which to provide a reference for anti-VEGF treatment and prognosis evaluation of wet AMD.